Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2011-10-03 |
Tigenix (Belgium) |
€4.95 million |
loan |
Madrid Network |
Allergic diseases - Immunological diseases |
Subvention |
2011-10-00 |
Viroblock (Switzerland) |
CHF 3.3 million (€2.6 million) |
series C financing round |
| Infectious diseases |
Fundraising |
2011-09-29 |
NeuroVive Pharmaceutical (Sweden) |
€1 million |
grant |
Eureka Eurostars program |
Cerebrovascular diseases - CNS diseases |
Grant |
2011-09-28 |
ProteoNic (The Netherlands) |
€6 million |
fundraising |
Fairbanks Investment Fund (USA) - existing shareholders |
Technology - Services |
Fundraising |
2011-09-26 |
Cytoo (France) Celletics (France) CEA (France) |
€7.6 million |
grant |
OSEO (France) |
Technology - Services |
Grant |
2011-09-23 |
CellMedica (UK) |
|
subvention |
the Wellcome Trust (UK) |
Infectious diseases |
Subvention |
2011-09-19 |
Malcisbo (Switzerland) |
CHF 3.6 million (€3 million) |
seed financing round |
Private investors - Business Angels - Zürcher Kantonalbank Startup Finance (Switzerland) - Redalpine Venture Partners AG (Switzerland) |
Infectious diseases |
Fundraising |
2011-09-15 |
Cellectis (France) |
€50 million |
fundraising |
FSI (France) - private investor Pierre Bastide |
Technology - Services |
Fundraising |
2011-09-13 |
AM-Pharma (The Netherlands) |
€29.2 million |
series D financing round |
Ysios Capital Partners (Spain) - Kurma Life Science Partners (France) - Abbott (USA) - Shire (UK) - BB Biotech Ventures (Switzerland) - Idinvest Partners (France) - Forbion Capital Partners (The Netherlands) - Inventages Venture Capital (UK-Switzerland-New Zealand-Bahamas) |
Inflammatory diseases |
Series D financing round |
2011-09-12 |
Diamyd Medical (Sweden) |
$3 million (€2.2 million) |
grant |
NIH (USA) |
Cancer - Oncology - CNS diseases |
Grant |
2011-09-12 |
Psioxus Therapeutics (UK) |
£1.8 million (€2.08 million) |
award |
Wellcome Trust (UK) |
Cancer - Oncology |
Subvention |
2011-09-09 |
Aprea (Sweden) |
SEK 20.4 million (€2.1 million) |
financing round |
current owners |
Cancer - Oncology |
Fundraising |
2011-09-07 |
PolyTherics (UK) |
£2.15 million (€2.4 million) |
financing round |
The financing round was led by Imperial Innovations Group plc (AIM: IVO), with participation from existing investor The Capital Fund, which is managed by YFM Equity Partners, and new investor Proven Health VCT PLC (LON: PHV).
|
Technology - Services |
Fundraising |
2011-09-07 |
Orphazyme (Denmark) |
€14 million |
series A financing round |
Aescap Venture (The Netherlands) - Novo A/S (Denmark) - Sunstone Capital (Denmark) |
Rare diseases |
Establishment of a new subsidiary in the EU |
2011-09-06 |
Amakem (Belgium) |
€ 18 million |
Series A financing round |
Forbion Capital Partners (The Netherlands) - Crédit Agricole Private Equity (France) - Vesalius BioCapital (Luxembourg) - LRM (Belgium) - PMV (Belgium) - Life Sciences Research Partners (Belgium) |
Ophtalmological diseases |
Fundraising |
2011-09-06 |
Theralpha (France) |
€2.55 million |
grant |
Eurobiomed cluster as part of the 12th FUI (Fond Unique Interministeriel) (France) - Conseil Général 06 (France) - Région PACA (France) - Communauté du Pays d\'Aix en Provence (France) - Clermont Communauté (France) |
CNS diseases |
Grant |
2011-09-05 |
Telormedix (Switzerland) |
€ 729,500 |
grant |
European Eurostars Programme (EU) |
Cancer - Oncology - Inflammatory diseases |
Grant |
2011-08-25 |
Mission Therapeutics (UK) |
£6 million |
series A round |
Sofinnova Partners (France) - Imperial Innovations (UK) - SR One (UK) - Roche Venture Fund (Switzerland) |
Cancer - Oncology |
Fundraising |
2011-08-25 |
Aleva Neurotherapeutics (Switzerland) |
€9.5 million |
Series A financing round |
BioMedInvest AG (Switzerland) - BB BIOTECH VENTURES III, L.P. Initiative Capital Romandie (Switzerland) - private investors |
Technology - Services - Neurodegenerative diseases |
Fundraising |
2011-08-24 |
Genfit (France) |
€5.3 million |
|
Yorkville Advisors (USA) |
Cardiovascular diseases - Metabolic diseases - Liver diseases |
Fundraising |